Levodopa/Carbidopa/Entacapone Orion (Carbidopa, Entacapone, Levodopa)

Levodopa/Carbidopa/Entacapone is indicated for Parkinson's disease and related motor complications. It acts within the dopaminergic pathway to improve motor control.

• Parkinson's disease (early or advanced): provides more stable dopaminergic stimulation when added to levodopa therapy.
• Motor fluctuations in Parkinson's disease: reduces OFF time and increases ON time without troublesome dyskinesia.
• Levodopa‑responsive Parkinsonian symptoms: enhances overall motor function and daily activity performance.

• Levodopa crosses the blood‑brain barrier and is converted to dopamine, restoring deficient central dopaminergic tone. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, limiting peripheral levodopa conversion and increasing its central availability. Entacapone blocks catechol‑O‑methyltransferase (COMT), prolonging levodopa plasma half‑life and further enhancing dopaminergic activity in the brain.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Dizziness: often related to orthostatic changes.
• Headache: transient and usually self‑limiting.
• Insomnia: difficulty falling or staying asleep.
• Orthostatic hypotension: drop in blood pressure upon standing.
• Vomiting: occasional severe gastrointestinal response.

Serious or Rare Side Effects

• Dyskinesia: involuntary movements that may be disabling.
• Hallucinations: visual or auditory disturbances, especially in older patients.
• Severe hypotension: can lead to syncope or falls.
• Neuroleptic malignant syndrome: rare but life‑threatening reaction.
• Hepatic enzyme elevation: monitor liver function tests.
• Anaphylaxis: rare allergic reaction requiring immediate medical attention.

Before initiating therapy, clinicians should consider several safety aspects.

• Monitor blood pressure: watch for orthostatic hypotension, especially after dose changes.
• Assess hepatic function: entacapone may affect liver enzymes; periodic testing is advised.
• Review psychiatric history: patients with prior hallucinations may be at higher risk.
• Adjust dose in renal impairment: consider reduced clearance and possible dose modification.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: risk of hypertensive crisis.
• Anticholinergic agents: may worsen confusion and cognitive impairment.
• CNS depressants: increased sedation and respiratory depression.
• Iron supplements: reduce levodopa absorption when taken simultaneously.
• High‑protein meals: decrease levodopa bioavailability and therapeutic effect.

Moderate Interactions (Monitor Closely)

• Selective MAO‑B inhibitors: may enhance dopaminergic activity.
• SSRIs/SNRIs: potential for serotonin syndrome when combined.
• Diuretics: may exacerbate orthostatic hypotension.
• Antihypertensives: additive blood‑pressure‑lowering effect.
• Antipsychotics: may diminish antiparkinson efficacy and require dose adjustment.